Program Overview
Retatrutide is a peptide-based molecule that presents specific formulation challenges when transitioning from injectable to oral dosage forms. The oral retatrutide program at ShiLai™ Healthcare addresses these challenges through systematic pre-formulation evaluation, excipient screening, and dosage-form development.
This program is positioned as a formulation development engagement. Commercial availability and regulatory status are subject to the specific program scope agreed with each B2B partner.
Formulation Development
Oral retatrutide formulation development at ShiLai™ Healthcare follows the structured workflow of the Oral Peptide Delivery Platform.
Pre-Formulation Assessment
Physicochemical characterisation of retatrutide to inform dosage-form selection and excipient strategy.
Excipient Screening
Evaluation of excipients for compatibility with retatrutide under formulation and storage conditions.
Dosage-Form Development
Development of prototype oral dosage forms — tablet, capsule, or other solid oral format — based on pre-formulation findings.
Prototype Evaluation
Assessment of prototype formulations for content uniformity, physical properties, and initial stability indicators.
Stability Considerations
Stability evaluation is a core component of the oral retatrutide formulation program. Key stability considerations include:
- Chemical stability under formulation and storage conditions
- Moisture sensitivity and packaging requirements
- Temperature stability profiling
- Excipient compatibility under accelerated conditions
- Shelf-life development based on stability data
Analytical Verification
Analytical verification throughout the oral retatrutide program applies HPLC and LC-MS methods for identity, purity, and content determination. Stability samples are monitored analytically to track formulation integrity over time. Batch documentation and COA are provided for each manufacturing batch.
OEM & CDMO Development
B2B partners can engage ShiLai™ Healthcare for oral retatrutide formulation development, scale-up, and OEM/CDMO manufacturing. Engagements are structured around the partner's program scope, target market, and documentation requirements. Private label and custom packaging support is available.
B2B only. No retail or individual orders.
Discuss an Oral Peptide Project